{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:58:00Z","timestamp":1793127480926,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006469","name":"Fund for the Development of Science and Technology","doi-asserted-by":"publisher","award":["0091\/2022\/A2"],"award-info":[{"award-number":["0091\/2022\/A2"]}],"id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.drudis.2025.104446","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T23:56:59Z","timestamp":1754438219000},"page":"104446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Development of LRRK2 inhibitors through computational strategies: a promising avenue for Parkinson\u2019s disease"],"prefix":"10.1016","volume":"30","author":[{"given":"Xiaoqing","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuoyan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9284-3667","authenticated-orcid":false,"given":"Huanxiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104446_b0005","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1021\/acs.jmedchem.2c01552","article-title":"The development and design strategy of leucine-rich repeat kinase 2 inhibitors: promising therapeutic agents for Parkinson's disease","volume":"66","author":"Tang","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104446_b0010","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1172\/JCI29178","article-title":"Diagnosis and treatment of Parkinson disease: molecules to medicine","volume":"116","author":"Savitt","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2025.104446_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106906","article-title":"Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease","volume":"141","author":"Cao","year":"2023","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2025.104446_b0020","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","article-title":"The epidemiology of Parkinson's disease","volume":"403","author":"Ben-Shlomo","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2025.104446_b0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40035-019-0165-9","article-title":"The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson's disease","volume":"8","author":"Pang","year":"2019","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.drudis.2025.104446_b0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","article-title":"LRRK2 in Parkinson disease: challenges of clinical trials","volume":"16","author":"Tolosa","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.drudis.2025.104446_b0035","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/bph.15575","article-title":"The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play","volume":"179","author":"Azeggagh","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drudis.2025.104446_b0040","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1093\/hmg\/ddu341","article-title":"Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models","volume":"23","author":"Li","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.drudis.2025.104446_b0045","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1042\/BST20200424","article-title":"Allosteric inhibition of LRRK2, where are we now","volume":"48","author":"Soliman","year":"2020","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.drudis.2025.104446_b0050","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/cmdc.202000872","article-title":"The tale of proteolysis targeting chimeras (PROTACs) for Leucine-Rich repeat Kinase 2 (LRRK2)","volume":"16","author":"Konstantinidou","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drudis.2025.104446_b0055","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1021\/acsmedchemlett.0c00453","article-title":"Degradation of LRRK2 in the treatment of Parkinson\u2019s disease","volume":"11","author":"Kargbo","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2025.104446_b0060","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1021\/acscentsci.2c01317","article-title":"Rational chemical design of molecular glue degraders","volume":"9","author":"Toriki","year":"2023","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.drudis.2025.104446_b0065","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1021\/acs.jmedchem.7b00045","article-title":"Discovery of a 3-(4-pyrimidinyl) indazole (MLi-2), an orally available and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor that reduces brain kinase activity","volume":"60","author":"Scott","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104446_b0070","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1021\/jm5014055","article-title":"Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor","volume":"58","author":"Henderson","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104446_b0075","doi-asserted-by":"crossref","first-page":"14912","DOI":"10.1021\/acs.jmedchem.3c01486","article-title":"Discovery of MK-1468: a potent, kinome-selective, brain-penetrant amidoisoquinoline LRRK2 inhibitor for the potential treatment of Parkinson's disease","volume":"66","author":"Kattar","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104446_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106324","article-title":"CADD, AI and ML in drug discovery: a comprehensive review","volume":"181","author":"Vemula","year":"2023","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.drudis.2025.104446_b0085","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jtice.2010.03.017","article-title":"Current developments of computer-aided drug design","volume":"41","author":"Huang","year":"2010","journal-title":"J Taiwan Inst Chem Eng"},{"key":"10.1016\/j.drudis.2025.104446_b0090","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1073\/pnas.0709098105","article-title":"Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase","volume":"105","author":"Deng","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2025.104446_b0095","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41586-020-2673-2","article-title":"Structure of LRRK2 in Parkinson\u2019s disease and model for microtubule interaction","volume":"588","author":"Deniston","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2025.104446_b0100","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1016\/j.cell.2021.05.004","article-title":"Structural analysis of the full-length human LRRK2","volume":"184","author":"Myasnikov","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2025.104446_b0105","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1126\/science.adi9926","article-title":"Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2","volume":"382","author":"Zhu","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.drudis.2025.104446_b0110","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00660-20","article-title":"The cell biology of LRRK2 in Parkinson's disease","volume":"41","author":"Usmani","year":"2021","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.drudis.2025.104446_b0115","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.tins.2021.12.002","article-title":"LRRK2 and idiopathic Parkinson's disease","volume":"45","author":"Rocha","year":"2022","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.drudis.2025.104446_b0120","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1093\/hmg\/dds522","article-title":"GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2","volume":"22","author":"Biosa","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.drudis.2025.104446_b0125","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/jnc.14566","article-title":"The Roc-COR tandem domain of leucine-rich repeat kinase 2 forms dimers and exhibits conventional Ras-like GTPase properties","volume":"147","author":"Mills","year":"2018","journal-title":"J Neurochem"},{"key":"10.1016\/j.drudis.2025.104446_b0130","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1021\/acschemneuro.3c00259","article-title":"Doubly constrained C-terminal of Roc (COR) domain-derived peptides inhibit leucine-rich repeat kinase 2 (LRRK2) dimerization","volume":"14","author":"Pathak","year":"2023","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.drudis.2025.104446_b0135","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1042\/BJ20100784","article-title":"Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)\/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization","volume":"430","author":"Dzamko","year":"2010","journal-title":"Biochem J"},{"key":"10.1016\/j.drudis.2025.104446_b0140","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41421-023-00639-8","article-title":"Pharmacology of LRRK2 with type I and II kinase inhibitors revealed by cryo-EM","volume":"10","author":"Zhu","year":"2024","journal-title":"Cell Discov"},{"key":"10.1016\/j.drudis.2025.104446_b0145","doi-asserted-by":"crossref","first-page":"8434","DOI":"10.1038\/s41467-024-52723-6","article-title":"RAB12-LRRK2 complex suppresses primary ciliogenesis and regulates centrosome homeostasis in astrocytes","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2025.104446_b0150","doi-asserted-by":"crossref","first-page":"8521","DOI":"10.1021\/acs.jcim.4c01267","article-title":"CACHE Challenge #1: targeting the WDR domain of LRRK2, a Parkinson's disease associated protein","volume":"64","author":"Li","year":"2024","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.drudis.2025.104446_b0155","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adt2050","article-title":"Type II kinase inhibitors that target Parkinson\u2019s disease\u2013associated LRRK2","volume":"11","author":"Raig","year":"2025","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2025.104446_b0160","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41531-023-00544-7","article-title":"Perspective on the current state of the LRRK2 field","volume":"9","author":"Taymans","year":"2023","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.drudis.2025.104446_b0165","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12964-024-01997-w","article-title":"Loss of LRRK2 activity induces cytoskeleton defects and oxidative stress during porcine oocyte maturation","volume":"23","author":"Wei","year":"2025","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.drudis.2025.104446_b0170","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/15548627.2019.1603548","article-title":"LRRK2 mutations impair depolarization-induced mitophagy through inhibition of mitochondrial accumulation of RAB10","volume":"16","author":"Wauters","year":"2020","journal-title":"Autophagy"},{"key":"10.1016\/j.drudis.2025.104446_b0175","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41420-020-0279-y","article-title":"Kinase inhibition of G2019S-LRRK2 enhances autolysosome formation and function to reduce endogenous alpha-synuclein intracellular inclusions","volume":"6","author":"Obergasteiger","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2025.104446_b0180","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00401-021-02325-z","article-title":"R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils","volume":"142","author":"Fan","year":"2021","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.drudis.2025.104446_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15252\/embj.201798099","article-title":"Rab29 activation of the Parkinson's disease-associated LRRK2 kinase","volume":"37","author":"Purlyte","year":"2018","journal-title":"EMBO J"},{"key":"10.1016\/j.drudis.2025.104446_b0190","doi-asserted-by":"crossref","first-page":"E9115","DOI":"10.1073\/pnas.1812196115","article-title":"LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis","volume":"115","author":"Eguchi","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2025.104446_b0195","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41531-022-00380-1","article-title":"Parkinson-causing mutations in LRRK2 impair the physiological tetramerization of endogenous \u03b1-synuclein in human neurons","volume":"8","author":"Fonseca-Ornelas","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.drudis.2025.104446_b0200","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1021\/bi3012077","article-title":"Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S","volume":"52","author":"Liu","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2025.104446_b0205","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1021\/acschemneuro.1c00726","article-title":"Molecular modeling study on the interaction mechanism between the LRRK2 G2019S mutant and type I Inhibitors by integrating molecular dynamics simulation, binding free energy calculations, and pharmacophore modeling","volume":"13","author":"Tan","year":"2022","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.drudis.2025.104446_b0210","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1021\/acschemneuro.3c00338","article-title":"Unveiling the selectivity mechanism of type-I LRRK2 inhibitors by computational methods: insights from binding thermodynamics and kinetics simulation","volume":"14","author":"Tan","year":"2023","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.drudis.2025.104446_b0215","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1021\/acs.jpcb.4c00335","article-title":"Decoding inhibitor egression from wild-type and G2019S mutant LRRK2 kinase: insights into unbinding mechanisms for precision drug design in Parkinson's disease","volume":"128","author":"Naskar","year":"2024","journal-title":"J Phys Chem B"},{"key":"10.1016\/j.drudis.2025.104446_b0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001427","article-title":"LRRK2 dynamics analysis identifies allosteric control of the crosstalk between its catalytic domains","volume":"20","author":"Weng","year":"2022","journal-title":"PLoS Biol"},{"key":"10.1016\/j.drudis.2025.104446_b0225","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1021\/acschembio.2c00868","article-title":"Capturing differences in the regulation of LRRK2 dynamics and conformational states by small molecule kinase inhibitors","volume":"18","author":"Weng","year":"2023","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.drudis.2025.104446_b0230","article-title":"Molecular dynamics studies reveal the structural impacts of LRRK2 R1441C and LRRK2 D1994A mutations in Parkinson's disease","volume":"40","author":"Rahman","year":"2024","journal-title":"Biochem Biophys Rep"},{"key":"10.1016\/j.drudis.2025.104446_b0235","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1073\/pnas.1817889116","article-title":"Crystal structure of the WD40 domain dimer of LRRK2","volume":"116","author":"Zhang","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2025.104446_b0240","doi-asserted-by":"crossref","first-page":"20421","DOI":"10.1039\/D0CP03171B","article-title":"How Parkinson's disease-related mutations disrupt the dimerization of WD40 domain in LRRK2: a comparative molecular dynamics simulation study","volume":"22","author":"Li","year":"2020","journal-title":"Phys Chem Chem Phys"},{"key":"10.1016\/j.drudis.2025.104446_b0245","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/13543776.2024.2378076","article-title":"Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson's disease: a patent review of the literature to date","volume":"34","author":"Morez","year":"2024","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.drudis.2025.104446_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115475","article-title":"Small-molecule LRRK2 inhibitors for PD therapy: current achievements and future perspectives","volume":"256","author":"Hu","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2025.104446_b0255","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk6191","article-title":"Inhibition of Parkinson\u2019s disease-related LRRK2 by type I and type II kinase inhibitors: activity and structures","volume":"9","author":"Sanz Murillo","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2025.104446_b0260","doi-asserted-by":"crossref","first-page":"9416","DOI":"10.1021\/jm301020q","article-title":"Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors","volume":"55","author":"Estrada","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104446_b0265","doi-asserted-by":"crossref","first-page":"5625","DOI":"10.1016\/j.bmcl.2012.06.104","article-title":"GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor","volume":"22","author":"Reith","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2025.104446_b0270","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.115.227587","article-title":"MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition","volume":"355","author":"Fell","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2025.104446_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113705","article-title":"Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: a review","volume":"224","author":"Sabe","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2025.104446_b0280","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1021\/jm300452p","article-title":"Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling","volume":"55","author":"Chen","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104446_b0285","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1016\/j.bmcl.2015.04.027","article-title":"Discovery of LRRK2 inhibitors using sequential in silico joint pharmacophore space (JPS) and ensemble docking","volume":"25","author":"Lang","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2025.104446_b0290","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1016\/j.bmcl.2017.03.098","article-title":"Discovery of LRRK2 inhibitors by using an ensemble of virtual screening methods","volume":"27","author":"Gancia","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2025.104446_b0295","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1021\/acschemneuro.1c00399","article-title":"Virtual screening and biological activity evaluation of new potent inhibitors targeting LRRK2 kinase domain","volume":"12","author":"Tan","year":"2021","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.drudis.2025.104446_b0300","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1016\/j.csbj.2021.06.013","article-title":"Structural binding site comparisons reveal crizotinib as a novel LRRK2 inhibitor","volume":"19","author":"Bolz","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.drudis.2025.104446_b0305","doi-asserted-by":"crossref","first-page":"12825","DOI":"10.3390\/ijms232112825","article-title":"Structure-based virtual screening and de novo design to identify submicromolar inhibitors of G2019S mutant of leucine-rich repeat kinase 2","volume":"23","author":"Park","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104446_b0310","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1021\/acschemneuro.2c00672","article-title":"Identification of LRRK2 inhibitors through computational drug repurposing","volume":"14","author":"Tan","year":"2023","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.drudis.2025.104446_b0315","doi-asserted-by":"crossref","first-page":"19775","DOI":"10.1039\/D4CP01762E","article-title":"Identification of novel LRRK2 inhibitors by structure-based virtual screening and alchemical free energy calculation","volume":"26","author":"Tan","year":"2024","journal-title":"Phys Chem Chem Phys"},{"key":"10.1016\/j.drudis.2025.104446_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116812","article-title":"Discovery of potent LRRK2 inhibitors by ensemble virtual screening strategy and bioactivity evaluation","volume":"279","author":"Gong","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2025.104446_b0325","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.70082","article-title":"Identification of potent leucine-rich repeat kinase 2 inhibitors by virtual screening and biological evaluation","volume":"105","author":"Shen","year":"2025","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.drudis.2025.104446_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2024.108810","article-title":"Application of artificial intelligence in drug design: a review","volume":"179","author":"Singh","year":"2024","journal-title":"Comput Biol Med"},{"key":"10.1016\/j.drudis.2025.104446_b0335","doi-asserted-by":"crossref","first-page":"7647","DOI":"10.1021\/acs.jmedchem.4c00520","article-title":"Concurrent optimizations of efficacy and blood-brain barrier permeability in new macrocyclic LRRK2 inhibitors for potential Parkinson's disease therapeutics","volume":"67","author":"Kim","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104446_b0340","doi-asserted-by":"crossref","first-page":"8800","DOI":"10.1039\/D3SC06880C","article-title":"In silico screening of LRRK2 WDR domain inhibitors using deep docking and free energy simulations","volume":"15","author":"Gutkin","year":"2024","journal-title":"Chem Sci"},{"key":"10.1016\/j.drudis.2025.104446_b0345","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1021\/acs.jcim.4c00601","article-title":"Subpocket similarity-based hit identification for challenging targets: application to the WDR domain of LRRK2","volume":"64","author":"Eguida","year":"2024","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.drudis.2025.104446_b0350","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1021\/acs.jcim.5c00588","article-title":"Active learning-guided hit optimization for the leucine-rich repeat kinase 2 WDR domain based on in silico ligand-binding affinities","volume":"65","author":"Gusev","year":"2025","journal-title":"J Chem Inf Model"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462500159X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462500159X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T11:54:02Z","timestamp":1772884442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135964462500159X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":70,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S135964462500159X"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104446","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of LRRK2 inhibitors through computational strategies: a promising avenue for Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104446"}}